Could a second drug save more lives in shock? major trial underway.
NCT ID NCT07063680
First seen Jan 05, 2026 · Last updated May 13, 2026 · Updated 23 times
Summary
This study tests whether adding argipressin to standard norepinephrine treatment helps people in intensive care with severe vasoplegic shock (a type of shock where blood vessels widen dangerously). About 390 adults will be randomly assigned to get argipressin or a placebo alongside usual care. The goal is to see if the combination improves survival, reduces kidney damage, and shortens the time patients need blood-pressure support.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH NOREPINEPHRINE-REFRACTORY VASOPLEGIC SHOCK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Dijon Bourgogne
RECRUITINGDijon, 21000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.